Pfizer, Africa CDC Strike COVID-19 Antiviral Pact: Report

Comments
Loading...
  • According to a Reuters report, Africa's public health body signed a memorandum of understanding with Pfizer Inc PFE, allowing African countries to access Paxlovid at cost. 
  • The news comes just a few months after researchers with the Drugs for Neglected Diseases Initiative reported that they were denied access to Paxlovid for use in a large study in 10 African countries that aim to find treatments for mild to moderate COVID-19.
  • According to a Nature report, Pfizer denied the access because it already had plans to conduct similar trials. 
  • Related: FDA Authorizes Pharmacists to Prescribe Pfizer's COVID-19 Therapy.
  • According to a November readout, Paxlovid reduced the risk of hospitalization or death by nearly 90% in unvaccinated adults. 
  • However, the benefit was less evident in patients who have already been vaccinated or are at a lower risk. 
  • In one subgroup analysis, Paxlovid showed a 57% reduction in hospitalizations and death for vaccinated patients with at least one risk factor for severe Covid. The difference was not statistically significant.
  • Price Action: PFE shares closed at $53.42 on Thursday.
  • Photo via Company
Overview Rating:
Speculative
50%
Technicals Analysis
66
0100
Financials Analysis
40
0100
Overview
Market News and Data brought to you by Benzinga APIs

Posted In:
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!